Hanging in the balance: Endogenous anti-inflammatory mechanisms in tissue repair and fibrosis

Journal of Pathology

Volumn 229, Issue 2, 2013, Pages 250-263

  Ariel, Amiram ^a   Timor, Orly ^a  

^a UNIVERSITY OF HAIFA   (Israel)

Author keywords

fibrosis; lipid mediators; macrophages; resolution of inflammation; TGF

Indexed keywords

ARACHIDONATE 15 LIPOXYGENASE; BILIRUBIN; CARBON MONOXIDE; HEME OXYGENASE 1; INTERLEUKIN 10; LIPID; LIPOCORTIN 1; NUCLEOSIDE; OSTEOGENIC PROTEIN 1; TRANSFORMING GROWTH FACTOR BETA;

DECISION MAKING; FIBROGENESIS; FIBROSIS; GAS; HEALING; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; IMMUNOREGULATION; INFLAMMATION; LEUKOCYTE; MACROPHAGE; MEDIATOR; NONHUMAN; POLYMORPHONUCLEAR CELL; PRIORITY JOURNAL; REVIEW; TISSUE REPAIR;

ANIMALS; APOPTOSIS; ARACHIDONATE 15-LIPOXYGENASE; FIBROSIS; HOMEOSTASIS; HUMANS; INFLAMMATION; MACROPHAGES; NEUTROPHILS; SIGNAL TRANSDUCTION; TRANSFORMING GROWTH FACTOR BETA; WOUND HEALING;

EID: 84871033704     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4108     Document Type: Review

References (206)

1. Nathan C, Ding A. Nonresolving inflammation. Cell 2010; 140: 871-882.
2. Serhan CN, Chiang N, Van Dyke TE,. Resolving inflammation: dual anti-inflammatory and pro-resolution lipid mediators. Nature Rev Immunol 2008; 8: 349-361. (Pubitemid 351595216)
3. Wynn TA,. Cellular and molecular mechanisms of fibrosis. J Pathol 2008; 214: 199-210. (Pubitemid 351160157)
4. Ueha S, Shand FH, Matsushima K,. Cellular and molecular mechanisms of chronic inflammation-associated organ fibrosis. Front Immunol 2012; 3: 71.
5. Gabbiani G,. The myofibroblast in wound healing and fibrocontractive diseases. J Pathol 2003; 200: 500-503. (Pubitemid 36818250)
6. Wynn TA, Barron L,. Macrophages: master regulators of inflammation and fibrosis. Semin Liver Dis 2010; 30: 245-257.
7. Barnes JL, Gorin Y,. Myofibroblast differentiation during fibrosis: role of NAD(P)H oxidases. Kidney Int 2011; 79: 944-956.
8. Liu G, Friggeri A, Yang Y, et al,. miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis. J Exp Med 2010; 207: 1589-1597.
9. Lian R, Chen Y, Xu Z, et al,. Soluble transforming growth factor-beta1 receptor II might inhibit transforming growth factor-beta-induced myofibroblast differentiation and improve ischemic cardiac function after myocardial infarction in rats. Coron Artery Dis 2010; 21: 369-377.
10. 1. Am J Respir Cell Mol Biol 1999; 21: 658-665. (Pubitemid 129502284)
11. Bratton DL, Henson PM,. Neutrophil clearance: when the party is over, clean-up begins. Trends Immunol 2011; 32: 350-357.
12. Serhan CN, Savill J,. Resolution of inflammation: the beginning programs the end. Nature Immunol 2005; 6: 1191-1197. (Pubitemid 43045627)
13. Byrne A, Reen DJ,. Lipopolysaccharide induces rapid production of IL-10 by monocytes in the presence of apoptotic neutrophils. J Immunol 2002; 168: 1968-1977. (Pubitemid 34135800)
14. Golpon HA, Fadok VA, Taraseviciene-Stewart L, et al,. Life after corpse engulfment: phagocytosis of apoptotic cells leads to VEGF secretion and cell growth. FASEB J 2004; 18: 1716-1718. (Pubitemid 39561661)
15. Huynh ML, Fadok VA, Henson PM,. Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-β1 secretion and the resolution of inflammation. J Clin Invest 2002; 109: 41-50. (Pubitemid 34052540)
16. Mitchell S, Thomas G, Harvey K, et al,. Lipoxins, aspirin-triggered epi-lipoxins, lipoxin stable analogues, and the resolution of inflammation: stimulation of macrophage phagocytosis of apoptotic neutrophils in vivo. J Am Soc Nephrol 2002; 13: 2497-2507.
17. Freire-de-Lima CG, Xiao YQ, Gardai SJ, et al,. Apoptotic cells, through transforming growth factor-beta, coordinately induce anti-inflammatory and suppress pro-inflammatory eicosanoid and NO synthesis in murine macrophages. J Biol Chem 2006; 281: 38376-38384. (Pubitemid 46041961)
18. A-Gonzalez N, Bensinger SJ, Hong C, et al,. Apoptotic cells promote their own clearance and immune tolerance through activation of the nuclear receptor LXR. Immunity 2009; 31: 245-258.
19. Pourcet B, Feig JE, Vengrenyuk Y, et al,. LXRalpha regulates macrophage arginase 1 through PU.1 and interferon regulatory factor 8. Circ Res 2011; 109: 492-501.
20. Schif-Zuck S, Gross N, Assi S, et al,. Saturated-efferocytosis generates pro-resolving CD11b(low) macrophages: modulation by resolvins and glucocorticoids. Eur J Immunol 2011; 41: 366-379.
21. Curran JN, Winter DC, Bouchier-Hayes D,. Biological fate and clinical implications of arginine metabolism in tissue healing. Wound Repair Regen 2006; 14: 376-386. (Pubitemid 44266592)
22. Munder M,. Arginase: an emerging key player in the mammalian immune system. Br J Pharmacol 2009; 158: 638-651.
23. Pesce JT, Ramalingam TR, Mentink-Kane MM, et al,. Arginase-1-expressing macrophages suppress Th2 cytokine-driven inflammation and fibrosis. PLoS Pathog 2009; 5: e1000371.
24. Piantadosi CA, Withers CM, Bartz RR, et al,. Heme oxygenase-1 couples activation of mitochondrial biogenesis to anti-inflammatory cytokine expression. J Biol Chem 2011; 286: 16374-16385.
25. Hegazi RA, Rao KN, Mayle A, et al,. Carbon monoxide ameliorates chronic murine colitis through a heme oxygenase 1-dependent pathway. J Exp Med 2005; 202: 1703-1713. (Pubitemid 41815876)
26. Sheikh SZ, Hegazi RA, Kobayashi T, et al,. An anti-inflammatory role for carbon monoxide and heme oxygenase-1 in chronic Th2-mediated murine colitis. J Immunol 2011; 186: 5506-5513.
27. Lee TS, Chau LY,. Heme oxygenase-1 mediates the anti-inflammatory effect of interleukin-10 in mice. Nature Med 2002; 8: 240-246.
28. Zheng L, Zhou Z, Lin L, et al,. Carbon monoxide modulates alpha-smooth muscle actin and small proline rich-1a expression in fibrosis. Am J Respir Cell Mol Biol 2009; 41: 85-92.
29. Zhou Z, Song R, Fattman CL, et al,. Carbon monoxide suppresses bleomycin-induced lung fibrosis. Am J Pathol 2005; 166: 27-37. (Pubitemid 40051657)
30. Biteman B, Hassan IR, Walker E, et al,. Interdependence of lipoxin A4 and heme-oxygenase in counter-regulating inflammation during corneal wound healing. FASEB J 2007; 21: 2257-2266. (Pubitemid 47026460)
31. Nascimento-Silva V, Arruda MA, Barja-Fidalgo C, et al,. Novel lipid mediator aspirin-triggered lipoxin A4 induces heme oxygenase-1 in endothelial cells. Am J Physiol Cell Physiol 2005; 289: C557-C563. (Pubitemid 41192664)
32. Zhang L, Wan J, Li H, et al,. Protective effects of BML-111, a lipoxin A(4) receptor agonist, on carbon tetrachloride-induced liver injury in mice. Hepatol Res 2007; 37: 948-956. (Pubitemid 47399924)
33. Lorigados CB, Soriano FG, Szabo C,. Pathomechanisms of myocardial dysfunction in sepsis. Endocr Metab Immune Disord Drug Targets 2010; 10: 274-284.
34. Simon F, Scheuerle A, Groger M, et al,. Effects of intravenous sulfide during porcine aortic occlusion-induced kidney ischemia/reperfusion injury. Shock 2011; 35: 156-163.
35. Tripatara P, Patel NS, Brancaleone V, et al,. Characterisation of cystathionine gamma-lyase/hydrogen sulphide pathway in ischaemia/reperfusion injury of the mouse kidney: an in vivo study. Eur J Pharmacol 2009; 606: 205-209.
36. Wallace JL, Ferraz JG, Muscara MN,. Hydrogen sulfide: an endogenous mediator of resolution of inflammation and injury. Antioxid Redox Signal 2012; 17: 58-67.
37. Huang J, Wang D, Zheng J, et al,. Hydrogen sulfide attenuates cardiac hypertrophy and fibrosis induced by abdominal aortic coarctation in rats. Mol Med Rep 2012; 5: 923-928.
38. Tan G, Pan S, Li J, et al,. Hydrogen sulfide attenuates carbon tetrachloride-induced hepatotoxicity, liver cirrhosis and portal hypertension in rats. PloS One 2011; 6: e25943.
39. Chen Y, Wang R,. The message in the air: hydrogen sulfide metabolism in chronic respiratory diseases. Respir Physiol Neurobiol (in press).
40. Perretti M, D'Acquisto F,. Annexin A1 and glucocorticoids as effectors of the resolution of inflammation. Nature Rev Immunol 2009; 9: 62-70.
41. Perretti M, Chiang N, La M, et al,. Endogenous lipid- and peptide-derived anti-inflammatory pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor. Nature Med 2002; 8: 1296-1302. (Pubitemid 35373563)
42. -/- mouse. FASEB J 2003; 17: 253-255.
43. Solito E, Kamal A, Russo-Marie F, et al,. A novel calcium-dependent proapoptotic effect of annexin 1 on human neutrophils. FASEB J 2003; 17: 1544-1546.
44. Maderna P, Yona S, Perretti M, et al,. Modulation of phagocytosis of apoptotic neutrophils by supernatant from dexamethasone-treated macrophages and annexin-derived peptide Ac(2-26). J Immunol 2005; 174: 3727-3733. (Pubitemid 40354084)
45. Damazo AS, Sampaio AL, Nakata CM, et al,. Endogenous annexin A1 counter-regulates bleomycin-induced lung fibrosis. BMC Immunol 2011; 12: 59.
46. Facio FN Jr, Burnett AL,. Protective effect of annexin-A1 against irreversible damage to cavernous tissue after cavernous nerve injury in the rat. BJU Int 2012; 110: 1346-1351.
47. Rider CC, Mulloy B,. Bone morphogenetic protein and growth differentiation factor cytokine families and their protein antagonists. Biochem J 2010; 429: 1-12.
48. Martinez FO, Sica A, Mantovani A, et al,. Macrophage activation and polarization. Front Biosci 2008; 13: 453-461. (Pubitemid 351599757)
49. Iyer SS, Cheng G,. Role of interleukin 10 transcriptional regulation in inflammation and autoimmune disease. Crit Rev Immunol 2012; 32: 23-63.
50. Bannenberg GL, Chiang N, Ariel A, et al,. Molecular circuits of resolution: formation and actions of resolvins and protectins. J Immunol 2005; 174: 4345-4355. (Pubitemid 40396017)
51. Chung EY, Liu J, Homma Y, et al,. Interleukin-10 expression in macrophages during phagocytosis of apoptotic cells is mediated by homeodomain proteins Pbx1 and Prep-1. Immunity 2007; 27: 952-964. (Pubitemid 350251222)
52. Voll RE, Herrmann M, Roth EA, et al,. Immunosuppressive effects of apoptotic cells. Nature 1997; 390: 350-351.
53. Garcia-Prieto E, Gonzalez-Lopez A, Cabrera S, et al,. Resistance to bleomycin-induced lung fibrosis in MMP-8 deficient mice is mediated by interleukin-10. PloS One 2010; 5: e13242.
54. Kitani A, Fuss I, Nakamura K, et al,. Transforming growth factor (TGF)-beta1-producing regulatory T cells induce Smad-mediated interleukin 10 secretion that facilitates coordinated immunoregulatory activity and amelioration of TGF-beta1-mediated fibrosis. J Exp Med 2003; 198: 1179-1188. (Pubitemid 37323383)
55. Kradin RL, Sakamoto H, Jain F, et al,. IL-10 inhibits inflammation but does not affect fibrosis in the pulmonary response to bleomycin. Exp Mol Pathol 2004; 76: 205-211. (Pubitemid 38569781)
56. Zeisberg M, Kalluri R,. Reversal of experimental renal fibrosis by BMP7 provides insights into novel therapeutic strategies for chronic kidney disease. Pediatr Nephrol 2008; 23: 1395-1398.
57. Sugimoto H, Yang C, LeBleu VS, et al,. BMP-7 functions as a novel hormone to facilitate liver regeneration. FASEB J 2007; 21: 256-264. (Pubitemid 46052564)
58. Zeisberg M, Hanai J, Sugimoto H, et al,. BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury. Nature Med 2003; 9: 964-968. (Pubitemid 36889942)
59. Wang S, Hirschberg R,. BMP7 antagonizes TGF-beta -dependent fibrogenesis in mesangial cells. Am J Physiol Renal Physiol 2003; 284: F1006-F1013. (Pubitemid 36443585)
60. Maric I, Kucic N, Turk Wensveen T, et al. BMP signaling in rats with TNBS-induced colitis following BMP7 therapy. Am J Physiol Gastrointest Liver Physiol 2012; 302: G1151-G1162.
61. Vukicevic S, Basic V, Rogic D, et al,. Osteogenic protein-1 (bone morphogenetic protein-7) reduces severity of injury after ischemic acute renal failure in rat. J Clin Invest 1998; 102: 202-214. (Pubitemid 28323847)
62. Riser BL, Najmabadi F, Perbal B, et al,. CCN3 (NOV) is a negative regulator of CCN2 (CTGF) and a novel endogenous inhibitor of the fibrotic pathway in an in vitro model of renal disease. Am J Pathol 2009; 174: 1725-1734.
63. Riser BL, Najmabadi F, Perbal B, et al,. CCN3/CCN2 regulation and the fibrosis of diabetic renal disease. J Cell Commun Signal 2010; 4: 39-50.
64. van Roeyen CR, Boor P, Borkham-Kamphorst E, et al,. A novel, dual role of CCN3 in experimental glomerulonephritis: pro-angiogenic and antimesangioproliferative effects. Am J Pathol 2012; 180: 1979-1990.
65. Lin Z, Natesan V, Shi H, et al,. A novel role of CCN3 in regulating endothelial inflammation. J Cell Commun Signal 2010; 4: 141-153.
66. Kular L, Rivat C, Lelongt B, et al,. NOV/CCN3 attenuates inflammatory pain through regulation of matrix metalloproteinases-2 and -9. J Neuroinflammation 2012; 9: 36.
67. Lin CG, Chen CC, Leu SJ, et al,. Integrin-dependent functions of the angiogenic inducer NOV (CCN3): implication in wound healing. J Biol Chem 2005; 280: 8229-8237. (Pubitemid 40349724)
68. Bennett RG,. Relaxin and its role in the development and treatment of fibrosis. Transl Res 2009; 154: 1-6.
69. Samuel CS, Zhao C, Bathgate RA, et al,. The relaxin gene-knockout mouse: a model of progressive fibrosis. Ann N Y Acad Sci 2005; 1041: 173-181. (Pubitemid 41132243)
70. Hewitson TD, Mookerjee I, Masterson R, et al,. Endogenous relaxin is a naturally occurring modulator of experimental renal tubulointerstitial fibrosis. Endocrinology 2007; 148: 660-669. (Pubitemid 46143169)
71. Unemori EN, Pickford LB, Salles AL, et al,. Relaxin induces an extracellular matrix-degrading phenotype in human lung fibroblasts in vitro and inhibits lung fibrosis in a murine model in vivo. J Clin Invest 1996; 98: 2739-2745. (Pubitemid 26427400)
72. Huang X, Gai Y, Yang N, et al,. Relaxin regulates myofibroblast contractility and protects against lung fibrosis. Am J Pathol 2011; 179: 2751-2765.
73. Jeyabalan A, Shroff SG, Novak J, et al,. The vascular actions of relaxin. Adv Exp Med Biol 2007; 612: 65-87.
74. Brecht A, Bartsch C, Baumann G, et al,. Relaxin inhibits early steps in vascular inflammation. Regul Pept 2011; 166: 76-82.
75. Ferlin A, Pepe A, Facciolli A, et al,. Relaxin stimulates osteoclast differentiation and activation. Bone 2010; 46: 504-513.
76. Dschietzig T, Bartsch C, Baumann G, et al,. RXFP1-inactive relaxin activates human glucocorticoid receptor: further investigations into the relaxin-GR pathway. Regul Pept 2009; 154: 77-84.
77. Ho TY, Yan W, Bagnell CA,. Relaxin-induced matrix metalloproteinase-9 expression is associated with activation of the NF-kappaB pathway in human THP-1 cells. J Leukoc Biol 2007; 81: 1303-1310. (Pubitemid 46702050)
78. Cosen-Binker LI, Binker MG, Cosen R, et al,. Relaxin prevents the development of severe acute pancreatitis. World J Gastroenterol 2006; 12: 1558-1568.
79. Rock KL, Kono H,. The inflammatory response to cell death. Annu Rev Pathol 2008; 3: 99-126. (Pubitemid 351488277)
80. Hasko G, Linden J, Cronstein B, et al,. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases. Nature Rev Drug Discov 2008; 7: 759-770.
81. Chan ES, Cronstein BN,. Adenosine in fibrosis. Mod Rheumatol 2010; 20: 114-122.
82. Cronstein BN, Naime D, Firestein G,. The antiinflammatory effects of an adenosine kinase inhibitor are mediated by adenosine. Arthritis Rheum 1995; 38: 1040-1045.
83. Chunn JL, Molina JG, Mi T, et al,. Adenosine-dependent pulmonary fibrosis in adenosine deaminase-deficient mice. J Immunol 2005; 175: 1937-1946. (Pubitemid 41023101)
84. Koroskenyi K, Duro E, Pallai A, et al,. Involvement of adenosine A2A receptors in engulfment-dependent apoptotic cell suppression of inflammation. J Immunol 2011; 186: 7144-7155.
85. Ohta A, Sitkovsky M,. Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 2001; 414: 916-920. (Pubitemid 34024743)
86. Garcia GE, Truong LD, Chen JF, et al,. Adenosine A(2A) receptor activation prevents progressive kidney fibrosis in a model of immune-associated chronic inflammation. Kidney Int 2011; 80: 378-388.
87. Csoka B, Selmeczy Z, Koscso B, et al,. Adenosine promotes alternative macrophage activation via A2A and A2B receptors. FASEB J 2012; 26: 376-386.
88. Blackburn MR, Lee CG, Young HW, et al,. Adenosine mediates IL-13-induced inflammation and remodeling in the lung and interacts in an IL-13-adenosine amplification pathway. J Clin Invest 2003; 112: 332-344. (Pubitemid 38063762)
89. Perez-Aso M, Chiriboga L, Cronstein BN,. Pharmacological blockade of adenosine A2A receptors diminishes scarring. FASEB J 2012; 26: 4254-4263.
90. Ehrchen J, Steinmuller L, Barczyk K, et al,. Glucocorticoids induce differentiation of a specifically activated, anti-inflammatory subtype of human monocytes. Blood 2007; 109: 1265-1274. (Pubitemid 46220679)
91. Barczyk K, Ehrchen J, Tenbrock K, et al,. Glucocorticoids promote survival of anti-inflammatory macrophages via stimulation of adenosine receptor A3. Blood 2010; 116: 446-455.
92. Brancaleone V, Dalli J, Bena S, et al,. Evidence for an anti-inflammatory loop centered on polymorphonuclear leukocyte formyl peptide receptor 2/lipoxin A4 receptor and operative in the inflamed microvasculature. J Immunol 2011; 186: 4905-4914.
93. Souza DG, Fagundes CT, Amaral FA, et al,. The required role of endogenously produced lipoxin A4 and annexin-1 for the production of IL-10 and inflammatory hyporesponsiveness in mice. J Immunol 2007; 179: 8533-8543.
94. Letterio JJ, Roberts AB,. TGF-beta: a critical modulator of immune cell function. Clin Immunol Immunopathol 1997; 84: 244-250. (Pubitemid 27398023)
95. Lawrence DA,. Latent-TGF-beta: an overview. Mol Cell Biochem 2001; 219: 163-170.
96. Ikushima H, Miyazono K,. Biology of transforming growth factor-beta signaling. Curr Pharm Biotechnol 2011; 12: 2099-2107.
97. Yan X, Chen YG,. Smad7: not only a regulator, but also a cross-talk mediator of TGF-beta signalling. Biochem J 2011; 434: 1-10.
98. Margadant C, Sonnenberg A,. Integrin-TGF-beta crosstalk in fibrosis, cancer and wound healing. EMBO Rep 2010; 11: 97-105.
99. Chen W, Frank ME, Jin W, et al,. TGF-beta released by apoptotic T cells contributes to an immunosuppressive milieu. Immunity 2001; 14: 715-725. (Pubitemid 32592419)
100. Fadok VA, Bratton DL, Konowal A, et al,. Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest 1998; 101: 890-898. (Pubitemid 28096086)
101. Ren Y, Savill J,. Proinflammatory cytokines potentiate thrombospondin-mediated phagocytosis of neutrophils undergoing apoptosis. J Immunol 1995; 154: 2366-2374.
102. Reidy MF, Wright JR,. Surfactant protein A enhances apoptotic cell uptake and TGF-beta1 release by inflammatory alveolar macrophages. Am J Physiol Lung Cell Mol Physiol 2003; 285: L854-L861. (Pubitemid 37158832)
103. Scannell M, Flanagan MB, deStefani A, et al. Annexin-1 and peptide derivatives are released by apoptotic cells and stimulate phagocytosis of apoptotic neutrophils by macrophages. J Immunol 2007; 178: 4595-4605. (Pubitemid 46492412)
104. Rani R, Smulian AG, Greaves DR, et al,. TGF-beta limits IL-33 production and promotes the resolution of colitis through regulation of macrophage function. Eur J Immunol 2011; 41: 2000-2009.
105. Ariel A, Fredman G, Sun YP, et al,. Apoptotic neutrophils and T cells sequester chemokines during immune response resolution through modulation of CCR5 expression. Nature Immunol 2006; 7: 1209-1216. (Pubitemid 44594317)
106. Johann AM, von Knethen A, Lindemann D, et al,. Recognition of apoptotic cells by macrophages activates the peroxisome proliferator-activated receptor-gamma and attenuates the oxidative burst. Cell Death Differ 2006; 13: 1533-1540. (Pubitemid 44210356)
107. Odegaard JI, Ricardo-Gonzalez RR, Goforth MH, et al,. Macrophage-specific PPARgamma controls alternative activation and improves insulin resistance. Nature 2007; 447: 1116-1120. (Pubitemid 47014427)
108. Fernandez-Boyanapalli RF, Frasch SC, McPhillips K, et al,. Impaired apoptotic cell clearance in CGD due to altered macrophage programming is reversed by phosphatidylserine-dependent production of IL-4. Blood 2009; 113: 2047-2055.
109. Kulkarni AA, Thatcher TH, Olsen KC, et al,. PPAR-gamma ligands repress TGFbeta-induced myofibroblast differentiation by targeting the PI3K/Akt pathway: implications for therapy of fibrosis. PloS One 2011; 6: e15909.
110. Burgess HA, Daugherty LE, Thatcher TH, et al,. PPARgamma agonists inhibit TGF-beta induced pulmonary myofibroblast differentiation and collagen production: implications for therapy of lung fibrosis. Am J Physiol Lung Cell Mol Physiol 2005; 288: L1146-L1153. (Pubitemid 40695441)
111. Hesse M, Cheever AW, Jankovic D, et al,. NOS-2 mediates the protective anti-inflammatory and antifibrotic effects of the Th1-inducing adjuvant, IL-12, in a Th2 model of granulomatous disease. Am J Pathol 2000; 157: 945-955. (Pubitemid 32109386)
112. Wynn TA, Cheever AW, Jankovic D, et al,. An IL-12-based vaccination method for preventing fibrosis induced by schistosome infection. Nature 1995; 376: 594-596.
113. Kaviratne M, Hesse M, Leusink M, et al,. IL-13 activates a mechanism of tissue fibrosis that is completely TGF-beta independent. J Immunol 2004; 173: 4020-4029. (Pubitemid 39280766)
114. Lee CG, Homer RJ, Zhu Z, et al,. Interleukin-13 induces tissue fibrosis by selectively stimulating and activating transforming growth factor beta(1). J Exp Med 2001; 194: 809-821. (Pubitemid 32983016)
115. Fichtner-Feigl S, Strober W, Kawakami K, et al,. IL-13 signaling through the IL-13alpha2 receptor is involved in induction of TGF-beta1 production and fibrosis. Nature Med 2006; 12: 99-106. (Pubitemid 43050083)
116. Lanone S, Zheng T, Zhu Z, et al,. Overlapping and enzyme-specific contributions of matrix metalloproteinases-9 and -12 in IL-13-induced inflammation and remodeling. J Clin Invest 2002; 110: 463-474. (Pubitemid 34919700)
117. Vaillant B, Chiaramonte MG, Cheever AW, et al,. Regulation of hepatic fibrosis and extracellular matrix genes by the Th response: new insight into the role of tissue inhibitors of matrix metalloproteinases. J Immunol 2001; 167: 7017-7026. (Pubitemid 33144197)
118. Madala SK, Pesce JT, Ramalingam TR, et al,. Matrix metalloproteinase 12-deficiency augments extracellular matrix degrading metalloproteinases and attenuates IL-13-dependent fibrosis. J Immunol 2010; 184: 3955-3963.
119. Bluestone JA, Abbas AK,. Natural versus adaptive regulatory T cells. Nature Rev Immunol 2003; 3: 253-257. (Pubitemid 37323210)
120. Sakaguchi S, Yamaguchi T, Nomura T, et al,. Regulatory T cells and immune tolerance. Cell 2008; 133: 775-787. (Pubitemid 351707693)
121. + regulatory T cells by TGF-β induction of transcription factor Foxp3. J Exp Med 2003; 198: 1875-1886. (Pubitemid 38032120)
122. - cells to develop suppressive activity: the role of IL-2, TGF-beta, and IL-10. J Immunol 2004; 172: 5213-5221. (Pubitemid 38542018)
123. + regulatory T cells. J Exp Med 2005; 201: 1061-1067. (Pubitemid 40524674)
124. + regulatory T lymphocytes promote lung fibrosis. Am J Respir Crit Care Med 2011; 184: 1270-1281.
125. Song L, Weng D, Liu F, et al,. Tregs promote the differentiation of Th17 cells in silica-induced lung fibrosis in mice. PloS One 2012; 7: e37286.
126. Arnold L, Henry A, Poron F, et al,. Inflammatory monocytes recruited after skeletal muscle injury switch into antiinflammatory macrophages to support myogenesis. J Exp Med 2007; 204: 1057-1069. (Pubitemid 46798150)
127. Perdiguero E, Sousa-Victor P, Ruiz-Bonilla V, et al,. p38/MKP-1-regulated AKT coordinates macrophage transitions and resolution of inflammation during tissue repair. J Cell Biol 2011; 195: 307-322.
128. Titos E, Rius B, Gonzalez-Periz A, et al,. Resolvin D1 and its precursor docosahexaenoic acid promote resolution of adipose tissue inflammation by eliciting macrophage polarization toward an M2-like phenotype. J Immunol 2011; 187: 5408-5418.
129. Shechter R, London A, Varol C, et al,. Infiltrating blood-derived macrophages are vital cells playing an anti-inflammatory role in recovery from spinal cord injury in mice. PLoS Med 2009; 6: e1000113.
130. Nagata S,. Autoimmune diseases caused by defects in clearing dead cells and nuclei expelled from erythroid precursors. Immunol Rev 2007; 220: 237-250. (Pubitemid 350045571)
131. Kruse K, Janko C, Urbonaviciute V, et al,. Inefficient clearance of dying cells in patients with SLE: anti-dsDNA autoantibodies, MFG-E8, HMGB-1 and other players. Apoptosis 2010; 15: 1098-1113.
132. Xiao YQ, Malcolm K, Worthen GS, et al,. Cross-talk between ERK and p38 MAPK mediates selective suppression of pro-inflammatory cytokines by transforming growth factor-beta. J Biol Chem 2002; 277: 14884-14893. (Pubitemid 34952562)
133. Patel VA, Lee DJ, Longacre-Antoni A, et al,. Apoptotic and necrotic cells as sentinels of local tissue stress and inflammation: response pathways initiated in nearby viable cells. Autoimmunity 2009; 42: 317-321.
134. Erwig LP, Henson PM,. Immunological consequences of apoptotic cell phagocytosis. Am J Pathol 2007; 171: 2-8. (Pubitemid 47339220)
135. Ravichandran KS, Lorenz U,. Engulfment of apoptotic cells: signals for a good meal. Nature Rev Immunol 2007; 7: 964-974. (Pubitemid 350166061)
136. Savill J, Dransfield I, Gregory C, et al,. A blast from the past: clearance of apoptotic cells regulates immune responses. Nature Rev Immunol 2002; 2: 965-975. (Pubitemid 37323217)
137. Ravichandran KS,. Beginnings of a good apoptotic meal: the find-me and eat-me signaling pathways. Immunity 2011; 35: 445-455.
138. Patel VA, Longacre A, Hsiao K, et al,. Apoptotic cells, at all stages of the death process, trigger characteristic signaling events that are divergent from and dominant over those triggered by necrotic cells: implications for the delayed clearance model of autoimmunity. J Biol Chem 2006; 281: 4663-4670. (Pubitemid 43847725)
139. Kim S, Elkon KB, Ma X,. Transcriptional suppression of interleukin-12 gene expression following phagocytosis of apoptotic cells. Immunity 2004; 21: 643-653. (Pubitemid 39487888)
140. Zhang Y, Kim HJ, Yamamoto S, et al,. Regulation of interleukin-10 gene expression in macrophages engulfing apoptotic cells. J Interferon Cytokine Res 2010; 30: 113-122.
141. Mukundan L, Odegaard JI, Morel CR, et al,. PPAR-delta senses and orchestrates clearance of apoptotic cells to promote tolerance. Nature Med 2009; 15: 1266-1272.
142. Dos Santos TA, Portes JdeA, Damasceno-Sa JC, et al. Phosphatidylserine exposure by Toxoplasma gondii is fundamental to balance the immune response granting survival of the parasite and of the host. PloS One 2011; 6: e27867.
143. Amarilyo G, Verbovetski I, Atallah M, et al,. iC3b-opsonized apoptotic cells mediate a distinct anti-inflammatory response and transcriptional NF-kappaB-dependent blockade. Eur J Immunol 2010; 40: 699-709.
144. Brissette MJ, Lepage S, Lamonde AS, et al,. MFG-E8 released by apoptotic endothelial cells triggers anti-inflammatory macrophage reprogramming. PloS One 2012; 7: e36368.
145. Aziz M, Jacob A, Matsuda A, et al,. Pre-treatment of recombinant mouse MFG-E8 downregulates LPS-induced TNF-alpha production in macrophages via STAT3-mediated SOCS3 activation. PloS One 2011; 6: e27685.
146. Weigert A, Johann AM, von Knethen A, et al,. Apoptotic cells promote macrophage survival by releasing the antiapoptotic mediator sphingosine-1- phosphate. Blood 2006; 108: 1635-1642. (Pubitemid 44316132)
147. Weigert A, Tzieply N, von Knethen A, et al,. Tumor cell apoptosis polarizes macrophages-role of sphingosine-1-phosphate. Mol Biol Cell 2007; 18: 3810-3819. (Pubitemid 47519475)
148. Bournazou I, Pound JD, Duffin R, et al,. Apoptotic human cells inhibit migration of granulocytes via release of lactoferrin. J Clin Invest 2009; 119: 20-32.
149. Pashover-Schallinger E, Aswad M, Schif-Zuck S, et al,. The atypical chemokine receptor D6 controls macrophage efferocytosis and cytokine secretion during the resolution of inflammation. FASEB J 2012; 26: 3891-3900.
150. Gabillet J, Millet A, Pederzoli-Ribeil M, et al,. Proteinase 3, the autoantigen in granulomatosis with polyangiitis, associates with calreticulin on apoptotic neutrophils, impairs macrophage phagocytosis, and promotes inflammation. J Immunol 2012; 189: 2574-2583.
151. Mantovani A, Sica A, Sozzani S, et al,. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 2004; 25: 677-686. (Pubitemid 39457982)
152. Amano H, Morimoto K, Senba M, et al,. Essential contribution of monocyte chemoattractant protein-1/C-C chemokine ligand-2 to resolution and repair processes in acute bacterial pneumonia. J Immunol 2004; 172: 398-409. (Pubitemid 38020494)
153. Li P, Garcia GE, Xia Y, et al,. Blocking of monocyte chemoattractant protein-1 during tubulointerstitial nephritis resulted in delayed neutrophil clearance. Am J Pathol 2005; 167: 637-649. (Pubitemid 41216350)
154. Tanaka T, Terada M, Ariyoshi K, et al,. Monocyte chemoattractant protein-1/CC chemokine ligand 2 enhances apoptotic cell removal by macrophages through Rac1 activation. Biochem Biophys Res Commun 2010; 399: 677-682.
155. Witko-Sarsat V, Reuter N, Mouthon L,. Interaction of proteinase 3 with its associated partners: implications in the pathogenesis of Wegener's granulomatosis. Curr Opin Rheumatol 2010; 22: 1-7.
156. Gardai SJ, McPhillips KA, Frasch SC, et al,. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell 2005; 123: 321-334. (Pubitemid 41457220)
157. Mantovani A, Sica A, Locati M,. Macrophage polarization comes of age. Immunity 2005; 23: 344-346. (Pubitemid 41443435)
158. Martinez FO, Helming L, Gordon S,. Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol 2009; 27: 451-483.
159. Corne J, Chupp G, Lee CG, et al,. IL-13 stimulates vascular endothelial cell growth factor and protects against hyperoxic acute lung injury. J Clin Invest 2000; 106: 783-791.
160. Berry A, Balard P, Coste A, et al,. IL-13 induces expression of CD36 in human monocytes through PPARgamma activation. Eur J Immunol 2007; 37: 1642-1652. (Pubitemid 46939499)
161. Huang JT, Welch JS, Ricote M, et al,. Interleukin-4-dependent production of PPAR-gamma ligands in macrophages by 12/15-lipoxygenase. Nature 1999; 400: 378-382. (Pubitemid 29344205)
162. Kang K, Reilly SM, Karabacak V, et al,. Adipocyte-derived Th2 cytokines and myeloid PPARdelta regulate macrophage polarization and insulin sensitivity. Cell Metab 2008; 7: 485-495. (Pubitemid 351729204)
163. Korns D, Frasch SC, Fernandez-Boyanapalli R, et al,. Modulation of macrophage efferocytosis in inflammation. Front Immunol 2011; 2: 57.
164. Lee YJ, Moon C, Lee SH, et al,. Apoptotic cell instillation after bleomycin attenuates lung injury through hepatocyte growth factor induction. Eur Respir J 2012; 40: 424-435.
165. Atabai K, Jame S, Azhar N, et al,. Mfge8 diminishes the severity of tissue fibrosis in mice by binding and targeting collagen for uptake by macrophages. J Clin Invest 2009; 119: 3713-3722.
166. Allavena P, Garlanda C, Borrello MG, et al,. Pathways connecting inflammation and cancer. Curr Opin Genet Dev 2008; 18: 3-10. (Pubitemid 351694444)
167. Barkan D, El Touny LH, Michalowski AM, et al. Metastatic growth from dormant cells induced by a col-I-enriched fibrotic environment. Cancer Res 2010; 70: 5706-5716.
168. Serhan CN, Jain A, Marleau S, et al,. Reduced inflammation and tissue damage in transgenic rabbits overexpressing 15-lipoxygenase and endogenous anti-inflammatory lipid mediators. J Immunol 2003; 171: 6856-6865. (Pubitemid 37532121)
169. Emerson MR, LeVine SM,. Experimental allergic encephalomyelitis is exacerbated in mice deficient for 12/15-lipoxygenase or 5-lipoxygenase. Brain Res 2004; 1021: 140-145. (Pubitemid 39158666)
170. Kronke G, Katzenbeisser J, Uderhardt S, et al,. 12/15-Lipoxygenase counteracts inflammation and tissue damage in arthritis. J Immunol 2009; 183: 3383-3389.
171. Uderhardt S, Herrmann M, Oskolkova OV, et al,. 12/15-Lipoxygenase orchestrates the clearance of apoptotic cells and maintains immunologic tolerance. Immunity 2012; 36: 834-846.
172. Shen J, Herderick E, Cornhill JF, et al,. Macrophage-mediated 15-lipoxygenase expression protects against atherosclerosis development. J Clin Invest 1996; 98: 2201-2208. (Pubitemid 26394192)
173. Gronert K, Maheshwari N, Khan N, et al,. A role for the mouse 12/15-lipoxygenase pathway in promoting epithelial wound healing and host defense. J Biol Chem 2005; 280: 15267-15278. (Pubitemid 40562883)
174. Kronke G, Reich N, Scholtysek C, et al,. The 12/15-lipoxygenase pathway counteracts fibroblast activation and experimental fibrosis. Ann Rheum Dis 2012; 71: 1081-1087.
175. Ariel A, Li PL, Wang W, et al,. The docosatriene protectin D1 is produced by TH2 skewing and promotes human T cell apoptosis via lipid raft clustering. J Biol Chem 2005; 280: 43079-43086. (Pubitemid 43049274)
176. Heydeck D, Thomas L, Schnurr K, et al,. Interleukin-4 and -13 induce upregulation of the murine macrophage 12/15-lipoxygenase activity: evidence for the involvement of transcription factor STAT6. Blood 1998; 92: 2503-2510. (Pubitemid 28452994)
177. Levy BD, Romano M, Chapman HA, et al,. Human alveolar macrophages have 15-lipoxygenase and generate 15(S)-hydroxy-5,8,11-cis-13-trans-eicosatetraenoic acid and lipoxins. J Clin Invest 1993; 92: 1572-1579. (Pubitemid 23273940)
178. Nassar GM, Morrow JD, Roberts LJ II, et al. Induction of 15-lipoxygenase by interleukin-13 in human blood monocytes. J Biol Chem 1994; 269: 27631-27634. (Pubitemid 24346597)
179. Merched AJ, Ko K, Gotlinger KH, et al,. Atherosclerosis: evidence for impairment of resolution of vascular inflammation governed by specific lipid mediators. FASEB J 2008; 22: 3595-3606.
180. Serhan CN, Yang R, Martinod K, et al,. Maresins: novel macrophage mediators with potent antiinflammatory and proresolving actions. J Exp Med 2009; 206: 15-23.
181. Chiang N, Fredman G, Backhed F, et al,. Infection regulates pro-resolving mediators that lower antibiotic requirements. Nature 2012; 484: 524-528.
182. Stables MJ, Shah S, Camon EB, et al,. Transcriptomic analyses of murine resolution-phase macrophages. Blood 2011; 118: e192-e208.
183. Yamada T, Tani Y, Nakanishi H, et al,. Eosinophils promote resolution of acute peritonitis by producing proresolving mediators in mice. FASEB J 2011; 25: 561-568.
184. Isobe Y, Arita M, Matsueda S, et al,. Identification and structure determination of novel anti-inflammatory mediator resolvin E3, 17,18-dihydroxyeicosapentaenoic acid. J Biol Chem 2012; 287: 10525-10534.
185. Serhan CN,. Novel lipid mediators and resolution mechanisms in acute inflammation: to resolve or not? Am J Pathol 2010; 177: 1576-1591.
186. Serhan CN, Krishnamoorthy S, Recchiuti A, et al,. Novel anti-inflammatory-pro-resolving mediators and their receptors. Curr Top Med Chem 2011; 11: 629-647.
187. Machado FS, Johndrow JE, Esper L, et al,. Anti-inflammatory actions of lipoxin A4 and aspirin-triggered lipoxin are SOCS-2 dependent. Nature Med 2006; 12: 330-334. (Pubitemid 43355082)
188. Russell R, Gori I, Pellegrini C, et al,. Lipoxin A4 is a novel estrogen receptor modulator. FASEB J 2011; 25: 4326-4337.
189. Wittwer J, Hersberger M,. The two faces of the 15-lipoxygenase in atherosclerosis. Prostaglandins Leukot Essent Fatty Acids 2007; 77: 67-77. (Pubitemid 47539103)
190. Godson C, Mitchell S, Harvey K, et al,. Cutting edge: lipoxins rapidly stimulate nonphlogistic phagocytosis of apoptotic neutrophils by monocyte-derived macrophages. J Immunol 2000; 164: 1663-1667. (Pubitemid 30108713)
191. Schwab JM, Chiang N, Arita M, et al,. Resolvin E1 and protectin D1 activate inflammation-resolution programmes. Nature 2007; 447: 869-874. (Pubitemid 46920139)
192. Krishnamoorthy S, Recchiuti A, Chiang N, et al,. Resolvin D1 binds human phagocytes with evidence for proresolving receptors. Proc Natl Acad Sci U S A 2010; 107: 1660-1665.
193. Ariel A, Chiang N, Arita M, et al,. Aspirin-triggered lipoxin A4 and B4 analogs block extracellular signal-regulated kinase-dependent TNF-alpha secretion from human T cells. J Immunol 2003; 170: 6266-6272. (Pubitemid 36682612)
194. Zhang B, Jia H, Liu J, et al,. Depletion of regulatory T cells facilitates growth of established tumors: a mechanism involving the regulation of myeloid-derived suppressor cells by lipoxin A4. J Immunol 2010; 185: 7199-7206.
195. 4 attenuate experimental renal fibrosis. FASEB J 2011; 25: 2967-2979.
196. Duffield JS, Hong S, Vaidya VS, et al,. Resolvin D series and protectin D1 mitigate acute kidney injury. J Immunol 2006; 177: 5902-5911. (Pubitemid 44628803)
197. Martins V, Valenca SS, Farias-Filho FA, et al,. ATLa, an aspirin-triggered lipoxin A4 synthetic analog, prevents the inflammatory and fibrotic effects of bleomycin-induced pulmonary fibrosis. J Immunol 2009; 182: 5374-5381.
198. Qu X, Zhang X, Yao J, et al,. Resolvins E1 and D1 inhibit interstitial fibrosis in the obstructed kidney via inhibition of local fibroblast proliferation. J Pathol 2012; DOI: 10.1002/path.4050.
199. Gonzalez-Periz A, Planaguma A, Gronert K, et al,. Docosahexaenoic acid (DHA) blunts liver injury by conversion to protective lipid mediators: protectin D1 and 17S-hydroxy-DHA. FASEB J 2006; 20: 2537-2539.
200. Yang XY, Wang LH, Mihalic K, et al,. Interleukin (IL)-4 indirectly suppresses IL-2 production by human T lymphocytes via peroxisome proliferator-activated receptor gamma activated by macrophage-derived 12/15-lipoxygenase ligands. J Biol Chem 2002; 277: 3973-3978. (Pubitemid 34968651)
201. Nencioni A, Wesselborg S, Brossart P,. Role of peroxisome proliferator-activated receptor gamma and its ligands in the control of immune responses. Crit Rev Immunol 2003; 23: 1-13. (Pubitemid 36875471)
202. Gautier EL, Chow A, Spanbroek R, et al,. Systemic analysis of PPARgamma in mouse macrophage populations reveals marked diversity in expression with critical roles in resolution of inflammation and airway immunity. J Immunol 2012; 189: 2614-2624.
203. Fernandez-Boyanapalli R, Frasch SC, Riches DW, et al,. PPARgamma activation normalizes resolution of acute sterile inflammation in murine chronic granulomatous disease. Blood 2010; 116: 4512-4522.
204. Wei J, Bhattacharyya S, Varga J,. Peroxisome proliferator-activated receptor gamma: innate protection from excessive fibrogenesis and potential therapeutic target in systemic sclerosis. Curr Opin Rheumatol 2010; 22: 671-676.
205. Marra F, Efsen E, Romanelli RG, et al,. Ligands of peroxisome proliferator-activated receptor gamma modulate profibrogenic and proinflammatory actions in hepatic stellate cells. Gastroenterology 2000; 119: 466-478. (Pubitemid 30621997)
206. Aoki Y, Maeno T, Aoyagi K, et al,. Pioglitazone, a peroxisome proliferator-activated receptor gamma ligand, suppresses bleomycin-induced acute lung injury and fibrosis. Respiration 2009; 77: 311-319.